Milind Javle presents the results of #tinengotinib in patients with #CCA #BTC and #FGFR2 gene fusions previously treated with other FGFR inhibitors at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social

The phase II FIGHT-202 trial’s final results reveal pemigatinib, a selective FGFR1-3 inhibitor, shows 37% ORR in patients with advanced/metastatic #CCA harboring #FGFR2 fusions/rearrangements (cohort A) 🌟

@myesmo.bsky.social #esmoopen

#Onco404 #Cancer #Kanser #Cholangiocarcinoma #Pemigatinib

24 and 16 significant differently methylated regions #DMRs were shown in exposed mothers and children respectively. 6 of these #DMRs eg #BCOR, #FGFR2 were common between mothers and children
8/11